You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 4, 2026

Surprise Inside! Thai Regulations for Food Products with Randomized Toys

Blind boxes and collectibles have become increasingly popular, driven by the excitement of not knowing which character or design will be revealed until the package is opened. While most visible in the art toy market, the same concept is also used in the food industry.

Confectionery, snacks, and other food products are sometimes sold with toys, character figures, cards, or other collectibles. A package might, for example, contain one of ten possible characters, with consumers knowing that an item is included but not which one they will receive. Some collections may also feature rare or “secret” items.

For food businesses, however, adding a randomized toy or collectible involves more than a marketing decision. The food, the nonfood item, and the randomized mechanism may each raise different regulatory considerations in Thailand.

Thai FDA Requirements for Nonfood Objects Packaged with Food

The main food regulatory consideration is Ministry of Public Health Notification No. 310 B.E. 2551 (2008), which regulates food packaged together with things or objects that are not food. Under Notification No. 310, certain nonfood objects may be packaged together with food where they fall within specified exceptions, including objects that serve the following purposes:

  • Maintaining the quality or standard of the food, such as a desiccant or oxygen absorber;
  • Serving as a seasoning or as part of food preparation, such as chili powder sachets or seasoning sachets contained in instant noodle packages; or
  • Functioning as an eating or food-preparation utensil, such as a spoon or fork included with instant noodles.

Other nonfood objects that do not fall within these categories generally should not be placed inside the food container together with the food. Where a toy, collectible, or other nonfood object is intended to be sold together with a food product, businesses should therefore carefully consider the nature of the object, how it is packaged and separated from the food, and the applicable Thai FDA requirements on a case-by-case basis.

In practice, the packaging arrangement should be assessed to ensure that the nonfood object does not create a health risk or cause consumers to mistakenly believe that it is edible. Depending on the specific packaging arrangement, this may involve placing the nonfood item outside the immediate food container, separately packaging it within the overall package, clearly separating the respective compartments, or attaching the promotional item externally to the food package.

When the Randomized Item Is a Toy

Where the nonfood item is a toy, a separate regulatory regime may also apply. Toys intended for children under 14 years of age may be subject to Thailand’s mandatory product safety requirements administered by the Thai Industrial Standards Institute (TISI), including TIS 685 on toys, depending on the characteristics and classification of the product. These requirements apply separately from the Thai FDA requirements applicable to the food and its packaging.

This is particularly relevant for imported products. A food product may need to satisfy Thai FDA requirements, while a toy included with it may separately require compliance with applicable TISI requirements.

In practice, businesses should therefore assess both the packaging arrangement under Thai FDA requirements and the toy itself under the applicable product safety requirements.

Randomized Toys, Different Values, and Other Legal Considerations

In situations where the toys are randomized, the fact that consumers do not know which toy they will receive does not, by itself, change the food regulatory analysis under Notification No. 310. Nor does the presence of randomness necessarily mean that the arrangement constitutes gambling.

However, separate legal considerations may arise depending on how the randomized mechanism is structured and marketed. One relevant factor may be the relative commercial value of the possible items. If the possible items have materially different values, the arrangement may raise different considerations than situations where the items are of broadly comparable value and the random element is primarily which character or design the consumer receives. For example, if most packages contain ordinary figures while a small number contain rare or “secret” items of substantially higher value, the difference in value may become relevant to the gambling-law analysis. Even where every consumer is guaranteed to receive an item, the element of chance may determine whether the item received is worth less than, equal to, or more than the amount paid. This may raise considerations relating to the risk of gaining or losing value under Thailand’s Gambling Act B.E. 2478 (1935), as the nature and value of the possible items, whether any additional prize or premium is offered by chance, and the overall structure of the promotion may also be relevant.

A related issue may arise where additional prizes or premiums are randomly included with the purchased product. Depending on the structure, this may fall within the provisions of the Gambling Act concerning the offering of premiums or prizes by chance, for which prior permission may be required.

The treatment of claw machines provides a useful comparison. Under the Gambling Act, as amended, certain amusement machines capable of producing a win-or-lose outcome may fall within the gambling regulatory framework. In a conventional claw-machine arrangement, a player pays for each attempt but may receive nothing if unsuccessful. The outcome therefore determines whether the player receives an item at all.

When assessing the regulatory implications of randomized items, the analysis should consider the overall structure of the transaction, including whether the consumer is guaranteed to receive an item, the relative value of the possible items, the role of chance in determining the outcome, and how the promotion is structured and marketed. Whether a particular arrangement raises issues under the Gambling Act will ultimately depend on its specific circumstances and should be assessed separately on a case-by-case basis.

One Product, Multiple Regulatory Considerations

A food product containing a randomized toy may appear to consumers as a single product, but businesses may need to consider several regulatory layers: Thai FDA requirements for the food and the packaging of a nonfood object with it, TISI safety and compliance requirements applicable to the toy, and other applicable laws that may be relevant to the structure of any randomized or chance-based promotional mechanism.

Each regime addresses a different regulatory issue. Compliance with Thai FDA requirements, for example, has no bearing on whether the toy complies with TISI requirements or whether the promotional mechanism raises issues under other laws.

Key Takeaways for Food Businesses

As food brands increasingly use collectibles, character collaborations, and blind-box-style concepts, these regulatory considerations should be addressed early in product development.

For food products containing randomized toys, businesses should consider what the nonfood item is, how it is packaged with and separated from the food, whether separate product standards apply to the toy, and how any randomized mechanism is structured and promoted.

Where the possible collectibles have materially different relative commercial values, additional legal review may also be appropriate, particularly where the promotion emphasizes the chance of obtaining a rare or high-value item.

Ultimately, what appears to consumers as a simple “surprise inside” may involve several regulatory layers. Identifying these considerations early in product development can help food businesses address potential regulatory issues before the product reaches the Thai market.

RELATED INSIGHTS​ 

December 15, 2023
As part of its membership in Lex Mundi, Tilleke & Gibbins has published an updated edition of its Guide to Doing Business in Thailand for 2023. This guide outlines the key factors for starting and operating a business in the Thai market. Issues covered include: Investment incentives Financial facilities Exchange controls Import and export regulations Structures for doing business Requirements for the Establishment of a Business Operation of the Business Cessation or Termination of the Business Labor legislation, relations, and supply Tax Immigration requirements This publication is part of Lex Mundi’s Country Guides series prepared by member firms in more than 100 jurisdictions worldwide. The guides serve as a useful resource for planning international business strategy and researching new markets. The full Guide to Doing Business in Thailand is available through the button below.
December 6, 2023
New regulatory requirements for medical device registration and notification in Laos are set to enter into force in the coming weeks under the plan found in Notification No. 9606 to implement Decision No. 1470/MOH on Registration and Notification of Medical Devices (Decision 1470). The notification, issued on October 25, 2023, by the Food and Drug Department (FDD) under the Ministry of Health (MOH), outlines the FDD’s strategic plan for phased-in registration and notification requirements for medical devices. In the first phase, starting January 1, 2024, the FDD will initiate the registration process for class C (moderate-high risk) and D (high risk) medical devices. Meanwhile, operators dealing with class A (low risk) and B (low-moderate risk) devices can continue applying for import permits without having to register the devices or notify the FDD. In the subsequent phase, starting January 1, 2025, operators will have to notify the FDD about class A devices and complete the registration process for class B devices. To prepare for these requirements, import-export companies in the pharmaceutical and medical products sector must submit a list of medical devices, including their classification based on the country of manufacture, to the FDD by December 15, 2023. This measure is aimed at enabling the FDD to streamline the collection, guidance, and preparation processes to ensure efficient registration within the set time frame. While import-export companies can still submit their lists after either December 15, 2023, or January 1, 2024 (the registration commencement date), registration may be delayed since the FDD will prioritize those who submit their lists by the December 15 deadline. The list of medical devices should encompass medical devices imported in the past as well as those intended for future import permission applications. During the initial registration stage (i.e., from January 1, 2024), import-export companies that are
October 25, 2023
Cambodia’s Ministry of Health (MOH) continues to increase awareness among the public and private sector of the need for strict healthcare regulations and strict enforcement to advance the quality of the country’s healthcare sector. In April 2023, the MOH issued a notification letter reminding advertisers of health products that they need to obtain a permit before advertising their products in Cambodia. On October 12, 2023, the MOH issued two press releases on continued noncompliance in the healthcare sector. The two press releases address the illegal advertising of both healthcare products and private healthcare services. The releases also address unlicensed healthcare professionals and general noncompliance by private healthcare services. These releases indicate that the MOH, in cooperation with local authorities, will substantially increase its enforcement efforts across Cambodia. Since October 12, several private healthcare clinics have had their operations closed and licenses suspended or revoked, signaling the ministry’s intent to enforce the legal framework. Noncompliant Advertising of Health Products The first press release focuses on the continued illegal advertising of health products and the advertising of unregistered health products. Health products include modern medicines, traditional medicines, health supplements, medical devices, cosmetics, and other products that prevent or treat diseases. The release highlights that the MOH has noticed ongoing unauthorized and illegal advertising, commenting that these are often found online and on social media. The noncompliant advertising referenced in the release includes advertising of health products without the required advertising permit, advertising products that are not properly registered with the MOH, and advertising by unlicensed companies and individuals. The MOH also states in the release that some advertisements are using inappropriate and noncompliant content that is not based on medical science and exaggerates the qualities of the health products—specifically mentioning skin-whitening cosmetics. The ministry’s press release also informs the public of
October 25, 2023
One significant development in the health sector in Indonesia is the use of information technology and communication in the implementation of health efforts—particularly digital health services such as telehealth and telemedicine integrated into the country’s National Health Information System. This development was addressed in a major new piece of legislation for the healthcare sector in Indonesia. Enacted in August 2023, Law No. 17 of 2023 concerning Health (the “Health Law”) provides the updates needed to support the development of healthcare services in Indonesia. Under the Health Law, health information system (HIS) providers must: Carry out processing of data and health information in the territory of Indonesia, except for certain limited and specific processing activities that may be conducted outside Indonesia when permitted by the relevant authorities and in compliance with relevant regulations. Ensure the reliability of its HIS, including availability, security, maintenance, and integration with Indonesia’s National Health Information System. Provide quality health data and information. Process data and health information, which includes planning, collection, storage, inspection, transfer, utilization, and destruction. Record its data- and information-processing history. Protect every person’s data and health information. Obtain approval from the relevant personal data subject or comply with relevant regulations if the processing of data and health information involves an individual’s health data. Inform the data owner if there is a failure to protect data and individual health information. The Health Law’s personal data protection requirements listed above appear to be aligned with the provisions in Law No. 27 of 2022 concerning Personal Data Protection (the “PDP Law”). Under this law, data and information relating to health are identified as “specific personal data,” the processing of which carries a high potential risk of impacting the relevant personal data subject. In the implementation of digital health services, patients’ personal data or medical records